CSL Ltd CMXHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing — Update
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027
CSL to Develop Kidney, Liver Disease Treatment With Alentis Therapeutics
Australia's CSL to Lower Medicaid Prices Amid U.S. Expansion
CSL's Share Price Hits Six-Month High on Guidance Beat
CSL Swings to $2.58 Billion Annual Loss on Write-Downs
CSL Cuts Annual Guidance, Signals $5 Billion of New Impairments — Update
Trading Information
- Previous Close Price
- $139.16
- Day Range
- $136.78–136.78
- 52-Week Range
- $63.84–141.83
- Bid/Ask
- $0.01 / $2,139.28
- Shares Outstanding
- 479.88M
- Market Cap
- $65.50B
- Volume/Avg
- 716 / 3,472
Key Statistics
- Price/Earnings (Normalized)
- 23.13
- Price/Sales
- 4.20
- Dividend Yield (Trailing)
- 2.07%
- Dividend Yield (Forward)
- 2.07%
- Dividend Payment Schedule
- Apr, Oct
- Total Yield
- 3.14%
Company Profile
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
Metric | CMXHF | SNY | 4502 |
|---|---|---|---|
Price/Earnings (Normalized) | 23.13 | 12.32 | 44.33 |
Price/Book Value | 4.43 | 1.38 | 1.48 |
Price/Sales | 4.20 | 1.94 | 2.32 |
Price/Cash Flow | 18.77 | 8.26 | 15.49 |
Price/Earnings
CMXHF
SNY
4502
Financial Strength
Metric | CMXHF | SNY | 4502 |
|---|---|---|---|
Quick Ratio | 0.88 | 0.21 | 0.52 |
Current Ratio | 2.21 | 1.12 | 1.15 |
Interest Coverage | −8.46 | 9.10 | 1.70 |
Quick Ratio
CMXHF
SNY
4502
Profitability
Metric | CMXHF | SNY | 4502 |
|---|---|---|---|
Return on Assets (Normalized) | 8.38% | 8.44% | 5.67% |
Return on Equity (Normalized) | 17.61% | 15.62% | 11.63% |
Return on Invested Capital (Normalized) | 11.10% | 12.02% | 7.93% |
Return on Assets
CMXHF
SNY
4502
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@@W^d? | LOCK|&wrY! | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|C^%#WKT | LOCK|#m@zn | $99B | |||
| Moderna Inc MRNA | LOCK|&vXx@&m | LOCK|S<h | $84B | |||
| argenx SE ADR ARGX | LOCK|gp@Z## | LOCK|$H | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|jPmb$HK | LOCK|w%& | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!M>#Gl&? | LOCK|tnL> | $31B | |||
| Incyte Corp INCY | LOCK|N!#Q!$ | LOCK|jg | $24B | |||
| BioNTech SE ADR BNTX | LOCK|mcY?#X | LOCK|%& | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|q$&BwD | LOCK|!T@g$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|FjvzB?? | LOCK|xZ> | $15B |